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or both. Sinus node dysfunction has been reported in
15% to 45% of patients at midterm follow-up after the
Fontan operation.2-5 In addition, patients with L-loop
(AV discordance) univentricular anatomy are prone to
the development of AV block.6-8 The inability to
maintain AV synchrony both before9 and after10 the
Fontan operation has been correlated with an adverse
late outcome. The presence of bradycardia and multi-
ple suture lines may further predispose patients to
atrial flutter after the Fontan procedure, a cause of
significant morbidity and mortality. Antibradycardia
and antitachycardia pacing may be helpful as a pri-
mary or adjunct modality in patients after the Fontan
operation.10-13
Bradyarrhythmias and tachyarrhythmias represent acause of significant morbidity in patients after the
Fontan operation.1-4 Bradyarrhythmias consist of
sinus node dysfunction, atrioventricular (AV) block,
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In general, pacing leads may be implanted through
an endocardial, transmural, or epicardial approach.
However, endocardial lead implantation may be
impossible in patients undergoing the Fontan opera-
tion because venous barriers limit access to the heart.
In addition, endocardial or transmural pacing may
result in thrombus formation and subsequent emboli
to either the pulmonary or systemic circulation.14,15
This is especially problematic in patients with a
right-to-left shunt across a fenestrated Fontan repair.
For these reasons, we have adopted the policy of only
using epicardial pacing leads in patients after the
Fontan operation. Although there are clear benefits to
providing AV synchrony and rate support, in selected
patients with Fontan physiology, there is little infor-
mation on the effects of performing a late thoracoto-
my or sternotomy. Furthermore, there is little known
about the long-term effectiveness of epicardial pacing
leads in patients with a single ventricle compared
with children with other forms of congenital heart
disease. The objective of this study was to compare
the early hospitalization and midterm follow-up of
epicardial pacing systems in Fontan patients and
patients undergoing similar lead implantation with 2-
ventricle physiology.
Methods
A complete search of the cardiac surgical and pacemaker
databases identified all patients who underwent epicardial
pacing lead implantation from January 1, 1983, to June 30,
2000, at The Children’s Hospital of Philadelphia. Patients
having additional reparative or palliative cardiac operations
within 30 days of the epicardial lead implantation were
excluded to evaluate the effects of either an isolated thoracot-
omy or sternotomy on the perioperative course. In addition,
patients who were admitted solely for a generator change
without lead revision were excluded. All hospital and opera-
tive records, as well as pacemaker clinic charts, were retro-
spectively reviewed. The perioperative period, operative peri-
od, and follow-up of epicardial pacing systems were
compared between patients with Fontan repair and all
remaining patients with 2-ventricle physiology (hereafter
referred to as non-Fontan).
Operative course. The epicardial leads were implanted by
means of standard surgical techniques, either through a mid-
line sternotomy, lateral thoracotomy, or subxiphoid approach
on the basis of previous cardiac operation and morphologic
cardiac position in the thorax. The subxiphoid approach was
generally used for an isolated ventricular lead implantation.
The ventricular lead was often fixed on the diaphragmatic
ventricular surface. The atrial lead was positioned on either
the right or left atrium, whichever afforded the best pacing
and sensing thresholds. During the last 4 years, our current
approach has generally been to place leads on the left atrial
appendage through a lateral thoracotomy in patients with
prior complex atrial operations.12 The surplus of leads is
addressed by creating loops of the electrode within the peri-
cardium and the pacemaker pocket.
Hospital course. The following demographic and periop-
erative variables were compared between patients in the
Fontan and non-Fontan groups: (1) anatomy; (2) age at pace-
maker implantation; (3) weight at implantation; (4) indication
for pacemaker; (5) anatomic chamber paced; (6) type of pace-
maker and leads; (7) surgical approach; (8) pacing and sens-
ing thresholds at implantation; (9) duration of ventilation;
(10) chest tube drainage; (11) length of stay; (12) discharge
pacing and sensing thresholds; and (13) frequency of read-
mission within 30 days. During lead implantation, the under-
lying P and R wave amplitudes, if present, were measured
with a pacing system analyzer (5311; Medtronic,
Minneapolis, Minn). The atrial and ventricular thresholds
were analyzed with the same pacing system analyzer. These
included the following: (1) the amplitude stimulation thresh-
old (minimum voltage delivered at a fixed pulse width of 0.5
ms that consistently captured the tissue); (2) the measured
current generated at this threshold voltage and pulse width;
and (3) the lead impedance measured at a pulse width of 0.5
Table I. Indications for pacing in the Fontan and non-
Fontan groups
AV Sinus node 
block dysfunction Other
Fontan cohort (n = 31)
Single LV, TGA 4 9
Single LV, NRGA 1 6
HLHS 0 5
Single RV 0 1
Heterotaxy 1 1
Other 0 3
Non-Fontan cohort (n = 56)
CCHB 17 0
s/p VSD 15 0
Long QT syndrome 4 0
Heterotaxy 1 5
s/p Aortic valvuloplasty 2 0
s/p Mitral valvuloplasty 1 0
s/p ASD 1 0
s/p ALCAPA 0 1
s/p Atrial switch 0 4
HOCM* 0 0 1
s/p OTHT 0 1
Other 3 0
LV, Left ventricle; TGA, transposition of the great arteries; NRGA, normally
related great arteries; HLHS, hypoplastic left heart syndrome; RV, right ven-
tricle; CCHB, congenital complete heart block; s/p, status post; VSD, ventric-
ular septal defect; ASD, atrial septal defect; ALCAPA, anomalous origin of the
left coronary artery from the pulmonary artery; HOCM, hypertrophic obstruc-
tive cardiomyopathy; OTHT, orthotopic heart transplantation.
*The child (15 kg) with hypertrophic obstructive cardiomyopathy had an
unexplained cardiac arrest and underwent an epicardially placed automatic
internal cardioverter defibrillator with backup ventricular pacing.
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ms and 5 V. Acute pacing characteristics were defined as
energy threshold (ET), lead impedance, and sensing at the
time of implantation. Discharge pacing characteristics were
assessed within 24 hours of hospital discharge.
Pacemaker follow-up. Pacing and sensing thresholds were
evaluated at 1 month, 3 months, and subsequently at 6-month
intervals. Outpatient evaluations consisted of real-time
telemetry of battery and lead measurements. Sensing and
pacing thresholds were determined by using either a
Medtronic 5300, Pacesetter (Sylmar, Calif), Intermedics
(Guidant, St Paul, Minn), or CPI (St Paul, Minn) pacing sys-
tem analyzer. Implant and follow-up data were compared
between the 2 patient groups (Fontan vs non-Fontan). Pacing
and sensing thresholds were compared at the time of implan-
tation, hospital discharge, 1 year, 2 years, 5 years, and the
most recent pacemaker follow-up visit.
Lead failure was defined as the need for replacement or
abandonment on the basis of the following: (1) fracture or
insulation break; (2) increasing pacing or sensing thresholds;
or (3) phrenic or myopotential stimulation. Infections were
classified separately into (1) superficial infection (with or
without positive blood culture) or (2) deep infection necessi-
Table II.  Early hospitalization after epicardial lead placement
Fontan Non-Fontan P value
Patients (n) 31 56
Age at implantation 7.5 y (4 mo-27 y) 2.7 y (1 d-44 y) <.05
Atrial leads (n) 27 9 <.05
Ventricular leads (n) 41 61 NS
AAI pacing (n) 5 2 NS
VVI pacing (n) 9 47 <.05
DDD pacing (n) 17 7 <.05
Chest tube drainage (d) 1 (0-20) 1 (0-6) NS
Length of intubation (d) 0 (0-1) 0 (0-46) NS
Length of stay (d) 3 (2-45) 4 (1-68) NS
Readmission <30 d (n) 8 15 NS
Late pleural effusions (n) 2 2 NS
NS, Not significant.
Fig 1. Probability of freedom from lead failure (Kaplan-Meier) in patients in the Fontan and non-Fontan groups. Fontan
leads are represented as solid lines, and non-Fontan leads are represented as hatched lines. The 1-, 2-, 5-, and 10-year
probability for lead failure in Fontan and non-Fontan pacing systems (including 95% CIs) were as follows: Fontan: 95%
(0.85-0.98); 95% (0.85-0.98), 60% (0.4-0.75), and 60% (0.4-0.75); non-Fontan: 95% (0.85-0.98), 88% (0.73-0.94), 80%
(0.62-0.9), and 72% (0.48-0.86). The numbers in parentheses represent the number of lead observations at that point for
each cohort.
tating generator removal. Lead data were censored for elec-
tive change, death, or orthotopic heart transplantation.
Definitions. Lead current (I) was calculated by using
Ohm’s law:
I = V/R
where V is the programmed pulse amplitude in volts and R is
the lead impedance measured in ohms. The ET is defined as
the least amount of energy that produces a consistent capture
outside the refractory period. The formula16 used to calculate
ET is as follows:
ET (µJ) = 
ET was used to facilitate comparison between acute and
chronic pacing thresholds.
Statistical analysis. Exploratory data analysis was per-
formed by using descriptive measures. Categoric variables
were expressed in terms of percentages with associated SDs.
Continuous variables were expressed in terms of means with
SDs if the term was normally distributed; skewed variables
were expressed as medians with ranges. The strength of a sta-
tistical association was measured by use of the χ2 test for cat-
egoric variables. When cell numbers were small, the Fisher
exact test was used. Statistical significance of the difference
between continuous variables was assessed by using a
Student t test of the means of normally distributed variables
and a Wilcoxon rank sum test for skewed distribution. A Cox
proportional hazards model was used to assess confounding
variables. Finally, Kaplan-Meier survival estimates were con-
structed for time-dependent variables by use of Stata 6.0 soft-
ware (Stata Corporation, College Station, Tex). Statistical
significance between curves was assessed by means of the
log rank test.
Results
Subjects. During the study period, 48 patients in the
Fontan group and 94 patients in the non-Fontan group
underwent epicardial pacing lead implantation.
Seventeen patients in the Fontan group and 38 patients
in the non-Fontan group were excluded as a result of
having had cardiac operations within the preceding 30
days. The remaining 31 patients in the Fontan group
and 56 patients in the non-Fontan group met the inclu-
sion criteria and were the basis for this study. Sixty-
eight leads (27 atrial and 41 ventricular) were implant-
ed in the 31 patients in the Fontan group during 65
operations. Seventy epicardial pacing leads (9 atrial
and 61 ventricular) were implanted in the 56 patients in
the non-Fontan group with 2 ventricles during 64 oper-
ations over the same time period. The anatomic diag-
nosis and indication for pacemaker implantation in the
2 study cohorts is shown in Table I. Of the 56 patients
in the non-Fontan group, 24 (43%) had no structural
heart disease.
V (volts)2 × dtp (ms) × 106

R (ohms) × 1000 ms/s
As an indication for pacing, sinus node dysfunction
was significantly more prevalent in patients in the
Fontan group, accounting for 80% of the pacemakers,
whereas AV block accounted for 78% of non-Fontan
group pacemakers. Although only 20% of the patients
in the Fontan group had AV block, ventricular pacing
was used in 84% (26/31) because of concerns of poten-
tial AV block associated with L-loop single-ventricle
heart disease or because of the concomitant use of
antiarrhythmic medications. Patients in the Fontan
group were significantly older (7.5 years; range, 4
months to 27 years) at the time of pacemaker implan-
tation compared with non-Fontan group subjects (2.7
years; range, 1 day to 44 years; P < .05). The mean age
at the time of the Fontan operation was 4.3 ± 4.4 years,
and the time from the Fontan operation to pacemaker
implantation was 5.5 ± 4.3 years. In 15 (48%) patients
the Fontan baffle was fenestrated at the time of the
operation, although it was patent in only 8 at the time
of the lead implantation. The median number of surgi-
cal procedures before pacemaker implantation in the
non-Fontan cohort was 1 (range, 0-4) and was signifi-
cantly less than the number of prior procedures per-
formed in the Fontan group (3; range, 1-5). Although
all patients in the Fontan group had prior operations,
only 25 (45%) of the patients in the non-Fontan group
had cardiac operations before the pacemaker implanta-
tion. The time from most recent cardiac operation to
the initial pacemaker implantation was not significant-
ly different in the non-Fontan cohort (5.4 ± 7.3 years)
compared with the Fontan cohort.
Operative techniques. Epicardial leads were
implanted with use of a thoracotomy (Fontan group,
37; non-Fontan group, 23), sternotomy (Fontan group,
24; non-Fontan group, 25), or a subxiphoid incision
(Fontan group, 7; non-Fontan group, 22). There were
no significant differences in the surgical approach
between the 2 groups. The types of epicardial leads
used were similar in the 2 groups. Steroid-eluting epi-
cardial leads were used in 40% and 35% of the Fontan
and non-Fontan lead insertions, respectively. The
Fontan epicardial leads included 59 myocardial screw-
in leads (Medtronic 4965, 5069, 5071, and 6917;
Pacesetter 1043K; Cordis 325) and 9 fishhook leads
(Medtronic 4951). The non-Fontan epicardial leads
included 58 myocardial screw-in leads (Medtronic
4965, 5069, 5071, and 6917; Pacesetter 1043K) and 12
fishhook leads (Medtronic 4951). 
Postoperative hospitalization. The perioperative
course after epicardial lead implantation was similar
between those patients with Fontan physiology and
those with 2-ventricle physiology. There was no differ-
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ence in the duration of intubation, chest tube drainage,
or length of stay between the 2 groups (Table II). Chest
tube drainage exceeding 5 days was observed in 3
(4.6%) patients in the Fontan group and 2 (3.1%)
patients in the non-Fontan group. All 3 of these patients
in the Fontan group underwent a thoracotomy for lead
implantation and remained in the hospital for at least 1
week, receiving diuretics and pleurocentesis. The
median stay after an isolated epicardial lead implanta-
tion was 3 days in both groups. One Fontan group
patient was hospitalized for 45 days with a deep pace-
maker pocket infection. One patient with dilated car-
diomyopathy and congenital complete AV block
remained hospitalized for 68 days because of a para-
lyzed diaphragm that required prolonged mechanical
ventilation. This patient eventually had a successful
diaphragm plication, resulting in extubation.
Of the 65 Fontan pacemaker implantations, readmis-
sion within 30 days of the hospital discharge occurred
in 8 (12%) cases. This was less than in the non-Fontan
cohort, in which 15 patients were readmitted after 64
(23%) pacemaker operations. The indications for read-
mission included the following: superficial infection
(Fontan group, 3; non-Fontan group, 9); pacemaker
noncapture (Fontan group, 1; non-Fontan group, 2);
protein-losing enteropathy (Fontan group, 1; non-
Fontan group, 0); pleural effusions (Fontan group, 2;
non-Fontan group, 2); postpericardiotomy syndrome
(Fontan group, 0; non-Fontan group, 1); lead fracture
(Fontan group, 0; non-Fontan group, 1); and generator
infection (Fontan group, 1; non-Fontan group, 0). No
difference in the perioperative course or readmission
rate was observed between the 25 patients with 2-ven-
tricle physiology who had prior cardiac operations and
the remaining 31 subjects in the non-Fontan group who
had not undergone a previous sternotomy or thoracoto-
my. In the 12 cases of superficial cellulitus, no organ-
ism was identifiable by means of peripheral blood cul-
ture, and all patients were discharged home within 7
days. In the 1 patient with a deep pocket infection, the
leads and generator were removed, and after 4 weeks of
intravenous antibiotics, a new pacing system was
implanted in a remote abdominal position. Of the 2
patients in the Fontan group readmitted with late pleu-
ral effusions, 1 was discharged home within 5 days on
oral diuretics and the other required 30 days of intra-
venous diuretics and pleurocentesis until resolution of
the effusions occurred.
Pacing and sensing characteristics. Lead survival
data are shown in Fig 1. Follow-up data from 6 months
or longer were available in 77% of the Fontan and 71%
of the non-Fontan epicardial leads. There was no sig-
nificant difference in the duration of epicardial lead fol-
low-up between the 2 study groups (Fontan group, 2.8
Fig 2. The cause of lead failure in patients in the Fontan (solid lines) and non-Fontan (hatched lines) groups dur-
ing the study period. The overall incidence of lead failure was 17% (24/138). There was no significant difference
in lead failure between patients in the Fontan and non-Fontan groups.
± 2.4 years; non-Fontan group, 3.7 ± 4.4 years). The 1,
2-, and 5-year lead survival for all epicardial systems
was 96%, 90%, and 70%, respectively. The presence of
Fontan physiology did not significantly alter the lead
survival curve (P = .2). The cause of lead failure was
similar between the Fontan and non-Fontan groups
(Fig 2) and was not confounded by the type of pacing
lead, as determined with a multivariate model (P =
.22).
Atrial lead failure secondary to poor sensing
occurred in 2 of the patients in the Fontan group. One
of these patients had a predominant junctional rhythm
without measurable P waves at the time of lead implan-
tation. This patient had atrial flutter with inappropriate-
ly recognized flutter P waves. No ventricular lead in
either group failed as a result of poor R wave sensing.
Phrenic pacing was reported in 1 Fontan ventricular
lead and 2 non-Fontan atrial leads. Lead fracture
occurred in 3 Fontan and 3 non-Fontan ventricular
leads and 1 additional Fontan atrial lead. Increasing
pacing thresholds necessitating replacement was
observed in 6 Fontan leads (1 atrial and 5 ventricular
leads) and 5 non-Fontan ventricular leads. None of the
29 subxiphoid implanted leads have failed over an
average follow-up of 2 years (1 month to 13.5 years).
There was no difference in lead survival between those
implanted through a thoracotomy or sternotomy.
Atrial epicardial leads. ETs were similar at implanta-
tion for the Fontan and non-Fontan systems (Fontan
group, 2.2 ± 1.5 µJ; non-Fontan group, 2.3 ± 3.6 µJ; P =
.57). There was a slight improvement in the ET for the
Fontan leads at 2 years of follow-up (1.4 ± 0.3 µJ), with-
out a significant change in the non-Fontan leads (3.4 ±
1.9 µJ). The lead impedances for patients in the Fontan
and non-Fontan groups were not significantly different
at implantation (Fontan group, 405 ± 127 Ω; non-Fontan
group, 352 ± 86 Ω; P = .28) and at 2 years of follow-up
(Fontan group, 408 ± 112 Ω; non-Fontan group, 338 ±
68 Ω; P = .27). Because the indication for pacing was
sinus node dysfunction, in many of the patients in the
Fontan group, P wave sensing could not always be per-
formed. The sensed P wave amplitudes were similar in
the Fontan and non-Fontan leads at implantation (Fontan
group [n = 21/27], 3.1 ± 1.5 mV; non-Fontan group [n =
6/9], 5.5 ± 2.0 mV, and at 2 years of follow-up (Fontan
group [n = 9/20], 2.6 ± 1.2 mV; non-Fontan group [n =
5/7], 2.9 ± 1.2 mV; P = .79).
Ventricular epicardial leads. The ETs at implantation
and 2 years of follow-up were not significantly differ-
ent between the Fontan and non-Fontan groups. Both
groups had a significant increase in ET between
implantation (Fontan group, 1.6 ± 1.3 µJ; non-Fontan
group, 2.1 ± 3.3 µJ; P = .11) and 2 years of follow-up
(Fontan group, 7.4 ± 6.5 µJ; non-Fontan group, 4.7 ±
4.4 µJ; P = .20). Similarly, the lead impedances for the
Fontan and non-Fontan groups were not significantly
different at implantation (Fontan group, 470 ± 155 Ω;
non-Fontan group, 421 ± 130 Ω; P = .11) and 2 years
of follow-up (Fontan group, 385 ± 78 Ω; non-Fontan
group, 383 ± 103 Ω; P = .94). Patients with complete
AV block and ventricular escapes of less than 30
beats/min were often unable to undergo intrinsic R
wave assessment. The sensed R wave amplitudes were
similar in the Fontan and non-Fontan leads at implan-
tation (Fontan group [n = 37/41], 11.7 ± 5.3 mV; non-
Fontan group [n = 53/61], 10.1 ± 5.1 mV) and at 2
years of follow-up (Fontan group, [n = 13/22], 8.6 ± 5.0
mV; non-Fontan group [n = 8/25], 7.3 ± 1.4 mV).
Steroid-eluting leads had similar ETs to non–steroid-
eluting leads at implantation (steroid, 1.9 ± 1.91 µJ;
nonsteroid, 2.0 ± 3.0 µJ). However, at 2 years of fol-
low-up, steroid-eluting leads had significantly lower
ETs than non–steroid-eluting leads (steroid [n = 20],
3.6 ± 3.7 µJ; nonsteroid [n = 41], 6.3 ± 5.8 µJ; P < .01).
No significant difference in the lead impedance
between steroid-eluting and non–steroid-eluting leads
was noted at implantation (steroid, 438 ± 142 Ω; non-
steroid, 423 ± 135 Ω) or 2 years of follow-up (steroid,
336 ± 52 Ω; nonsteroid, 409 ± 98 Ω).
Long-term follow-up. Among the 31 patients in the
Fontan group, there were 3 late deaths, and 1 patient
received a heart transplant. Two of the deaths in the
Fontan group were related to low cardiac output caused
by ventricular dysfunction. The other death in the
Fontan group occurred suddenly in a patient with a his-
tory of medically refractory atrial flutter. No patient in
the Fontan group died during pacemaker implantation
or as a result of pacemaker failure. Of the 3 deaths in
the Fontan group, 2 had DDD generators, and 1 had a
VVI pacemaker.
Among the 56 patients in the non-Fontan group with
a pacemaker, 3 have ultimately died, and 1 underwent
heart transplantation. None of the 3 deaths were pace-
maker related. One patient with congenital AV block
and hydrops died early in life. One patient with tetral-
ogy of Fallot had aortic valve endocarditis and subse-
quent left ventricular dysfunction. This patient eventu-
ally died while awaiting a heart transplant. The third
patient was a newborn with complete common AV
canal and late-onset AV block who died as a result of
bronchopulmonary dysplasia.
Six patients in the Fontan group and 12 patients in
the non-Fontan group required generator revisions with
the same epicardial lead or leads as a result of battery
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patients undergoing the Fontan operation, as well as to
evaluate the long-term survival of epicardial leads in a
large cohort of pediatric patients.
We observed no difference in the length of chest tube
drainage or hospital stay after epicardial lead place-
ment in patients in the Fontan group compared with
patients in the non-Fontan group, regardless of the sur-
gical approach. Additionally, having a prior thoracoto-
my or sternotomy did not alter the perioperative pace-
maker implantation among the non-Fontan cohort. The
median length of time that the chest tube was required
after 68 epicardial lead placements in 31 patients in the
Fontan group was 1 day. Furthermore, we observed no
difference in the readmission rate or incidence of late
effusions among the 2 groups. Only 2 patients in the
Fontan group required readmission for late pleural
effusions. On the basis of our study, a late thoracotomy
or sternotomy for epicardial pacemaker implantation
can be achieved with minimal risk of infection or effu-
sion in all patients.
Lead failure occurred in 17% of all implanted epi-
cardial leads and was typically a result of either a
fracture or increasing pacing threshold. We observed
no difference in the lead failure rate between those
patients with biventricular anatomy and those with
Fontan physiology. The 2-year survival of the leads
was similar in patients in the Fontan group (90%) and
patients in the non-Fontan group (89%). None of the
29 subxiphoid-implanted leads in this study failed.
This approach generally minimizes the daily traction
imposed by respiration and arm movement that might
otherwise occur with leads implanted through a thora-
cotomy. Beyond the first few years of lead implanta-
tion, the failure rate was similar to that of previously
reported epicardial pacing studies, achieving a proba-
bility of lead survival at 5 and 10 years of 70% and
65%, respectively.7,19,20
The midterm pacing and sensing characteristics of
the leads were comparable between the Fontan and
non-Fontan groups. Exit block with increasing pacing
thresholds occurred infrequently, although in all cases,
the leads were nonsteroid eluting. No patient with a
steroid-eluting lead had exit block. This is similar to a
study by Cutler and colleagues,21 who found no evi-
dence of exit block in 22 patients with steroid-eluting
epicardial pacing leads who were followed up for 6
years. The use of steroid-eluting leads in reducing the
ET without significantly altering the lead impedance
should prolong the battery life. Even in subjects in the
non-Fontan group, epicardially pacing young children
for as long as possible should reduce the risk of venous
obstruction. 
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depletion. No patient in either cohort was lost to fol-
low-up.
Discussion
Because the Fontan operation is increasingly used
for a variety of lesions with a functional single ventri-
cle, 6% to 10% of patients may require antitachycar-
dia pacemakers, antibradycardia pacemakers, or both
within the first 5 years after the operation.1,5,10 Sinus
node dysfunction and atrial flutter have been shown to
increase in frequency with time from the Fontan oper-
ation.3,5 Patients after the Fontan operation may have
junctional rhythm with loss of AV synchrony, or alter-
natively, patients with L-loop univentricular hearts
may acquire complete AV block. The inability to
maintain AV synchrony limits atrial contribution to
ventricular filling, a situation that can be remedied by
cardiac pacing.
Although endocardial pacing is generally prefer-
able to epicardial pacing because of lower current
values and pacing thresholds, there are certain cir-
cumstances in which the use of transvenous leads is
impractical or contraindicated. Disadvantages
include the limited vascular access in small children,
risk of venous obstruction, and the need for growth
accommodation. It may be impossible to gain
venous access to the ventricle in patients undergoing
the Fontan operation who require ventricular pacing.
Furthermore, newer modifications to the Fontan
operation, such as the extracardiac conduit, may also
exclude venous access to the atrium. Although suc-
cessful transmural atrial pacing has been previously
reported in patients undergoing the Fontan operation
with the use of bipolar atrial leads, this approach
continues to place patients at risk for systemic
embolus, pulmonary embolus, or both, necessitating
the use of warfarin.11
With improvements in lead technology, such as
steroid-eluting leads, the pacing thresholds are very
similar to conventional endocardial leads.17 In addition,
positioning atrial epicardial leads on the left atrial
appendage in patients who have previously undergone
extensive right atrial operations has been shown to sig-
nificantly lower ETs.12 However, the disadvantage of
epicardial lead placement relates to the extensive dis-
section often needed to achieve adequate sensing and
pacing thresholds. Speculation has been raised that per-
forming the lateral thoracotomy itself may result in a
high incidence of pleural effusions,12 a frequent finding
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Limitations. This was a retrospective study. No
patient in the Fontan group underwent endocardial or
transmural lead placement for comparison. The earliest
steroid-eluting lead was implanted in 1994, obviating
long-term comparison between steroid-eluting and
non–steroid-eluting epicardial leads.
Conclusions 
We conclude that epicardial leads can be safely
placed in patients having undergone the Fontan opera-
tion at no additional risk compared to non-Fontan sub-
jects. The incidence of pleural effusions after a late tho-
racotomy in Fontan patients appears to be minimal. The
use of epicardial leads is a reliable method of long-term
pacing in children, has applicability in every child, and
avoids the inherent risk of thromboembolism associat-
ed with transvenous leads.
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